The U.K. biotech sector likes to talk up its leading position among European countries in terms of funds raised and products in development, but Britain’s lead isn’t all that secure - recent data from consultancy EY show life science companies based in other European countries are almost as successful as U.K.-based ones at attracting investment and R&D.
In EY’s 2014 “State of the [U.K.] Nation” report, released earlier this month, Swiss companies were in fact just ahead...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?